Related Experiment Videos
Pharmacologic studies on W10,294A, a new bronchodilator
The Journal of Pharmacology and Experimental Therapeutics
|December 1, 1977
Summary
W10,294A is a potent bronchodilator that effectively reverses bronchoconstriction. This compound demonstrated superior potency and duration compared to aminophylline, with fewer cardiovascular side effects.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Drug Discovery
Background:
- Bronchoconstriction is a key feature of respiratory diseases like asthma.
- Existing bronchodilators have limitations, necessitating the search for novel agents.
- Histamine, methacholine, and acetylcholine are common mediators of bronchoconstriction.
Purpose of the Study:
- To evaluate the bronchodilator and antihistaminic properties of W10,294A.
- To compare the efficacy and safety of W10,294A with aminophylline.
- To investigate the mechanism of action of W10,294A.
Main Methods:
- In vitro studies using guinea pig trachea for smooth muscle relaxation and antihistaminic activity.
- In vivo studies in anesthetized dogs measuring resistance and dynamic compliance.
- Oral administration studies in dogs to assess duration of action.
- Comparative studies against aminophylline in various models.
Main Results:
- W10,294A is a potent antagonist of histamine-, methacholine-, and acetylcholine-induced bronchoconstriction.
- It exhibits direct smooth muscle relaxant and modest antihistaminic effects.
- W10,294A demonstrated greater potency and longer duration than aminophylline in reversing bronchospasm in dogs.
- Cardiovascular effects were significantly less pronounced with W10,294A compared to aminophylline.
Conclusions:
- W10,294A is a highly effective bronchodilator with a favorable profile.
- Its potency, duration of action, and reduced cardiovascular impact suggest therapeutic potential.
- Further investigation into W10,294A as a treatment for obstructive airway diseases is warranted.